CTKB
Cytek Biosciences, Inc. Healthcare Medical Devices
10/12
Innovation Score
Patent Activity
3/3
11 patents found
FUZZY
Cash Runway
3/3
431 months of cash remaining based on current burn rate.
Cash on hand: $262.2M
Cash on hand: $262.2M
Revenue Trajectory
1/3
Revenue: $204.2M
YoY Growth: +6.5%
YoY Growth: +6.5%
Management Quality
3/3
Insider ownership: 25.3%
SBC/Revenue: 32.7%
No reverse splits detected
SBC/Revenue: 32.7%
No reverse splits detected
Key Metrics
Market Cap
$486.9M
Revenue
$204.2M
Revenue Growth (YoY)
+6.5%
Cash on Hand
$262.2M
Cash Runway
431 months
Shares Outstanding
129.1M
Insider Ownership
25.3%
SBC / Revenue
32.7%
Sector / Industry
Healthcare / Medical Devices
Patents (11)
Match type: FUZZY — company name matched partially; verify assignee
- Cell sorter with pivotal scuppers
- Smart flow cytometers with self monitoring fluidics
- Methods of forming multi-color fluorescence-based flow cytometry panel
- Methods and apparatus for full spectrum flow cytometer
- Compact detection module for flow cytometers
7-Step Risk Assessment
How CTKB maps to our micro cap methodology:
- Innovation Signal 11 patents identified. This suggests the company is investing in defensible IP.
- Cash Runway Check 431 months of runway. Comfortable buffer for execution.
- Revenue Trajectory +6.5% YoY growth on $204.2M revenue. Positive but moderate growth.
- Management Alignment Insiders hold 25.3% of shares. SBC is 32.7% of revenue.
- Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
- Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
- Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $486.9M company.
Financial Detail
Free Cash Flow
$6.4M
FCF Yield
1.3%
Return on Equity
-20.9%
Debt / Equity
8.4%
Gross Margin
51.7%
Profit Margin
-36.2%
Operating Margin
-41.8%
Price / Book
1.49
Current Ratio
4.69
Dividend Yield
None
Share Count Change (YoY)
N/A
Share Count Change (3yr)
N/A
Quality Flags
Low Debt
FCF Positive
Free Cash Flow Trend
Insufficient Data
Consecutive Years FCF Positive
0
Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.
Last screened: 2026-06-20